Medical News Today -
27 Nov 2013 12:00
BTG plc (LSE: BTG), the specialist healthcare company, has announced that the US Food and Drug Administration (FDA) has approved Varithenaâ„¢ (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system.1 Varithenaâ„¢ (formerly known as Varisolve PEM) is a pharmaceutical-grade, low-nitrogen, polidocanol foam dispensed from a proprietary canister device.
Share this Article